Oxford conference on innovation and technology transfer for global health
Download
Sponsored Links
This presentation is the property of its rightful owner.
1 / 89

Oxford Conference on Innovation and Technology Transfer for Global Health PowerPoint PPT Presentation


  • 105 Views
  • Uploaded on
  • Presentation posted in: General

Oxford Conference on Innovation and Technology Transfer for Global Health. University of Oxford. Bridging the Gap in Global Health Innovation: From Needs to Access. 9-13 September 2007. Health Innovation: The neglected capacity of developing countries to address neglected diseases.

Download Presentation

Oxford Conference on Innovation and Technology Transfer for Global Health

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Oxford conference on innovation and technology transfer for global health

Oxford Conference on Innovation and Technology Transfer for Global Health

University of Oxford


Bridging the gap in global health innovation from needs to access

Bridging the Gap in Global Health Innovation:From Needs to Access

9-13 September 2007


Health innovation the neglected capacity of developing countries to address neglected diseases

Health Innovation: The neglected capacity of developing countries to address neglected diseases

Carlos Morel

Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil


Plenary lecture

Plenary lecture

PURPOSE:To address all round tables of this Oxford Conference through the biased lens of a developing country citizen,researcher and decision-maker


1 st round table

1st Round Table


Global neglected and most neglected diseases who msf

Global, neglected and most neglected diseases (WHO & MSF)

Most neglected diseases(e.g. dengue, Chagas)

World pharmaceutical market(>$600 bn in 2005)

Neglected diseases(e.g. malaria, tuberculosis)

Global diseases(e.g. measles, diabetes)


Understanding global inequalities

Understanding global inequalities

Private health spending

Malaria cases

Dorling D (2007) Worldmapper: The Human Anatomy of a Small Planet. PLoS Medicine 4(1)13-18


Oxford conference on innovation and technology transfer for global health

Public opinion sees illegal drugs as a major problem all over Africa


Oxford conference on innovation and technology transfer for global health

On the other hand the need to pay for medical and health care seems to vary among countries (e.g. Uganda x Mali)


Neglected tropical diseases

Neglected tropical diseases

“The neglected tropical diseases are a group of 13 major disablingconditions that are among the most common chronic infectionsin the world's poorest people”

Hotez et al, Control of Neglected Tropical Diseases. N Engl J Med 2007, 357:1018-1027


Oxford conference on innovation and technology transfer for global health

Hotez et al, Control of Neglected Tropical Diseases. N Engl J Med 2007, 357:1018-1027


Relationships between science technology and production

Relationships between science, technology and production

Francisco Sagasti. Knowledge and innovation for development. The Sisyphus challenge of the 21st century, Cheltenham, UK; Northampton, USA:Edward Elgar, 2004. 151 pages


The sisyphus challenge in chile

The Sisyphus challenge in Chile…

Scientometrics72(1):93-103, 2007


The sisyphus challenge in chile1

The Sisyphus challenge in Chile…

“Developing countries share disbelief about the benefits of the endogenous production of science as a tool for economical growth. Hence, public policies to strengthen science and technology and promote the culture of innovation are, in general, weak and sometimes incoherent”

Scientometrics72(1):93-103, 2007


And in brazil

… and in Brazil

Morel et al (2007) The road to recovery. Nature 449, in press


Entrepreneurship as conceptual orphan

Entrepreneurship as ‘Conceptual Orphan’

“While the role of entrepreneurs and entrepreneurship has never been denied, its most debilitating facet is its limited, often cursory, coverage by the great thinkers on economics and business”…

Hine and Kapeleris (2006) Edward Elgar Publishing Ltd, UK, 259 pp. ISBN-10 1 84376 584 4


Entrepreneurship as conceptual orphan1

Entrepreneurship as ‘Conceptual Orphan’

Hine and Kapeleris (2006) Edward Elgar Publishing Ltd, UK, 259 pp. ISBN-10 1 84376 584 4


2 nd round table

2nd Round Table


Forms of knowledge and modes of innovation jensen et al 2007

Forms of knowledge and modes of innovation (Jensen et al, 2007)

  • I. Science, Technology and Innovation - STI

    • Based on the production and use of codified scientific and technical knowledge (“explicit knowledge”)

    • High priority to the production of “know-why”

    • Emphasis on the use of information and communication technology as tools for codifying and sharing knowledge

    • “Global” knowledge

Jensen MB, Johnson B, Lorenz E, Lundvall BA: Forms of knowledge and modes of innovation. Research Policy 2007, 36:680-693.


Forms of knowledge and modes of innovation jensen et al 20071

Forms of knowledge and modes of innovation (Jensen et al, 2007)

  • II. Doing, Using and Interacting - DUI

    • Relies on informal processes of learning and experience-based know how

    • High priority to the production of “know how” and “know who”

    • Strategies emphasizing the role played by informal communication and communities of practice in mobilizing tacit knowledge for problem-solving and learning

    • “Local” knowledge

Jensen MB, Johnson B, Lorenz E, Lundvall BA: Forms of knowledge and modes of innovation. Research Policy 2007, 36:680-693.


Forms of knowledge and modes of innovation jensen et al 20072

Forms of knowledge and modes of innovation (Jensen et al, 2007)

  • Know-what

  • Know-why

  • Know-how

  • Know-who

Emphasis on STI mode

Emphasis on DUI mode

Jensen MB, Johnson B, Lorenz E, Lundvall BA: Forms of knowledge and modes of innovation. Research Policy 2007, 36:680-693.


Forms of knowledge and modes of innovation jensen et al 2007 situations

Forms of knowledge and modes of innovation (Jensen et al, 2007): Situations

  • Situation IOrganizations are specialized in one of the two modes

  • Situation II Organizations try to manage the two modes

STI

DUI

STI

DUI

Jensen MB, Johnson B, Lorenz E, Lundvall BA: Forms of knowledge and modes of innovation. Research Policy 2007, 36:680-693.


Forms of knowledge and modes of innovation jensen et al 2007 indicators

Forms of knowledge and modes of innovation (Jensen et al, 2007): Indicators

Jensen MB, Johnson B, Lorenz E, Lundvall BA: Forms of knowledge and modes of innovation. Research Policy 2007, 36:680-693.


National innovation learning systems

National Innovation & Learning Systems


National innovation learning systems1

National Innovation & Learning Systems

ACTIVENIS (Korea)

PASSIVE NLS (Brazil)


Gdp per capita korea x brazil 1975 2004

GDP per capitaKorea x Brazil, 1975-2004

2004

Brazil: 7.531

Korea: 18.840

1975

Brazil: 5.502

Korea: 3.722


Science failures

Science failures

  • Why: Insufficient knowledge

  • Example: Unknown vaccines

    • Viral: Dengue, avian flu

    • Bacterial: Leprosy, TB

    • Parasitic: Malaria, leishmaniases, trypanosomiases

  • Need: Basic or “user-inspired” research; “Mode 2” of knowledge production (*)

  • Innovation modality

    • New or improved products

    • New R&D strategies: PDPs; PPPs (Brazil: Innovation Law)

(*) Gibbons M, Limoges C, Nowotny H, Schwartzman S, Scott P, Trow M: The new production of knowledge: the dynamics of science and research in contemporary societies. London; Thousand Oaks; New Delhi: SAGE Publications; 1994


Market failures

Market failures

  • Why: High costs prevent access to existing interventions or the development and production of cheaper ones

  • Example: antiretrovirals; combination therapies; new TB drugs

  • Need: Cheaper production processes; new funding strategies

  • Innovation modalities

    • New methods/processes of production

    • New funding policies (Push: PDPs; Pull: Global Funds)

    • New budgeting policies

      • Increasing health budget (e.g. Brazilian taxation on financial transactions)

      • Decreasing health expenses (e.g. antiretrovirals IPR negotiations between Governments and private sector)


Public health failures

Public health failures

  • Why: Lack of good governance or sound priorities; corruption; crises/war; cultural or religious factors; etc., prevent the access to cheap and readily available interventions

  • Examples

    • Infectious diseases: polio vaccination (Religious or cultural factors); leprosy chemotherapy (Brazil: wrong policy, lack of priority)

    • Chronic diseases: obesity, tobacco (lobbying by multinational companies)

  • Needs: Education, civil society mobilization, human rights approach

  • Innovation modality: Process, strategy innovation

    • National Vaccination Days; WHO Tobacco Convention; educational TV campaigns (e.g. Brazilian soap operas with health messages); Tanzania’s experience in priority-setting in health systems (*)

(*) Savigny, Kasale, Mbuya, and Reid (2004) Fixing Health Systems


A health failures innovations needed country actions matrix

A “health failures / innovations needed / country actions” matrix


A health failures innovations needed country actions matrix1

A “health failures / innovations needed / country actions” matrix


Fighting science failures knowledge gaps

Fighting science failures(knowledge gaps)


Fighting science failures knowledge gaps1

Fighting science failures(knowledge gaps)


A health failures innovations needed country actions matrix2

A “health failures / innovations needed / country actions” matrix


Fighting market failures resources gap

Fighting market failures (resources gap)


A health failures innovations needed country actions matrix3

A “health failures / innovations needed / country actions” matrix


Fighting public health failures best practices gap

Fighting public health failures(best practices gap)


A health failures innovations needed country actions matrix4

A “health failures / innovations needed / country actions” matrix


3 rd round table

3rd Round Table


Components of health innovation

Components of health innovation


Components of health innovation1

Components of health innovation


Innovative developing countries idcs

Innovative Developing Countries, IDCs

(*) Morel et al (2005) Innovation Strategy Today 1(1):1-15http://www.biodevelopments.org/innovation/index.htm


Innovative developing countries idcs1

Innovative Developing Countries, IDCs

(*) Morel et al (2005) Innovation Strategy Today 1(1):1-15http://www.biodevelopments.org/innovation/index.htm


Ldcs idcs oecd and the six components of health innovation

LDCs  IDCs  OECD and the six components of health innovation

6 components or determinants

LDCs  IDCs  OECD

(*) Morel et al (2005) Innovation Strategy Today 1(1):1-15http://www.biodevelopments.org/innovation/index.htm


The power of the emerging idcs

The power of the emerging... IDCs!


Health innovation networks

Health Innovation Networks


Oxford conference on innovation and technology transfer for global health

  • Developing Country Vaccine Manufactures’ Network

    • Brazil, Cuba, China, India, Indonesia, Mexico

  • WHO Developing Countries’ Vaccine Regulators Network

    • Brazil, China, Cuba, India, Indonesia, Russia, South Africa, South Korea, Thailand

Morel et al (2005) Science 309:401-404, 2005


National health innovation system

National Health Innovation System

Morel et al (2005) Science 309:401-404, 2005


Collaborative research network on leprosy involving brazilian researchers

Collaborative research network on leprosy involving Brazilian researchers

Morel et al (2007) The road to recovery. Nature 449, in press


4 th round table

4th Round Table


Health technology innovation major historical periods

Health technology innovation: Major historical periods

  • 1850-early 1900s’: Era of the public sector

    • Epitomized by the work of Pasteur

  • 1900s’-1970s’: Era of the private sector

    • Emerged in Germany & chemical companies

  • 1970s’-2000: Era of public sector reawakening

    • United Nations: WHO Special Programmes (HRP, TDR)

    • USA: Bayh-Dole Act; NIH budget increase

  • 2000- : Era of public-private partnerships (PPPs)

    • Product Development Partnerships (PDPs)

    • Innovative Developing Countries (IDCs)

    • Health Innovation Networks

Mahoney, R & Morel, C. (2006) A Global Health Innovation System (GHIS). Innovation Strategy Today 2(1):1-12


Global health ppps product based and product development based

Global health PPPs: product-based and product-developmentbased

Buse K, Walt G (2000) Global public-private partnerships: parts I & II Bull.World Health Organ. 78(4): 549-561 & 78(5): 699-709


Mary moran s pharmaceutical r d policy project

Mary Moran’s Pharmaceutical R&D Policy Project


Mary moran s pharmaceutical r d policy project1

Mary Moran’s Pharmaceutical R&D Policy Project

Mary Moran’s team identified three categories of major players in drug development for neglected and most neglected diseases

  • Multinational drug companies

    • 32 projects

    • Working with PPPs or alone on a non-commercial basis

  • Smaller scale commercial firms

    • 60-plus projects

    • Working with PPPs on a commercial basis

  • Drug development PPPs

    • 47 projects

    • Working with large and small companies


Mary moran s pharmaceutical r d policy project2

Mary Moran’s Pharmaceutical R&D Policy Project


Types of global health partnerships

Types of global health partnerships

There is today a large number of global health PPPs focusing on neglected and most neglected diseases. They are quite different in terms of vision and goals.

  • Partnerships focusing at reducing financial risks of drug development

    • MMV; TB Alliance

  • Partnerships focusing on public health and capacity building of endemic countries

    • UN Special Programmes (HRP; TDR)

    • Developing Country Vaccine Manufactures’ Network

    • WHO Developing Countries’ Vaccine Regulators Network

  • Partnerships addressing both goals

    • DNDi


Health pdps broad range of mandates

Health PDPs: Broad range of mandates

“Development as Growth” (*)

“Development as Freedom” (A. Sen)(*)

  • Partnership focuses on product development and registration; minimal or no involvement of developing countries

    • Most PDPs involving multinational drug companies

  • Partnership’s mandate includes issues such as capacity building; training; involvement of endemic country institutions and public health

    • WHO/country networks

    • UN Special Programmes

(*) Personal communication - Margaret Chon, Seattle University School of Law


A spectrum of global health ppps

A spectrum of global health PPPs

Nature of PPPs’visions and mandates

Focus on financial risk reduction

Focus on increasing capacity and public health


A spectrum of global health ppps1

A spectrum of global health PPPs

Nature of PPPs’visions and mandates

Focus on financial risk reduction

Focus on capacity building and public health

DCVR (Developing Countries' Vaccine Regulators) Network


Mary moran s pharmaceutical r d policy project ppp timelines

Mary Moran’s Pharmaceutical R&D Policy Project: PPP timelines


Mary moran s pharmaceutical r d policy project performance metrics

Mary Moran’s Pharmaceutical R&D Policy Project: Performance metrics

Standard industry metrics, as used by Moran’s project, should be regarded as just one component of a broader set of metrics when analyzing Global PPPs of different nature

  • Involvement of developing country partners

    • National Innovation Systems

    • GLP, GCP, GMP

    • Regulatory agencies

  • Strengthening local health systems & services


5 th round table

5th Round Table


Intellectual property rights and innovation in developing countries

Intellectual property rights and innovation in developing countries

IP strongly protected

IP not protected

Chen Y, Puttitanun T: Intellectual property rights and innovation in developing countries. Journal of Development Economics 2005, 78:474-493.


Intellectual property rights and innovation in developing countries1

Intellectual property rights and innovation in developing countries

IP protection due to external pressure

IP protection by country decision

IP policy in transition

Chen Y, Puttitanun T: Intellectual property rights and innovation in developing countries. Journal of Development Economics 2005, 78:474-493.


Ip and compulsory licences

IP and compulsory licences


Ip management in health

IP management in health

To address IP management and licensing, one of the six components of health innovation, developing countries need to train human resources and strengthen their institutions in this critical area


Public health innovation and ip

Public Health, Innovation and IP

Resolution of the World Health Assembly

Intergovernmental Working Group on Public Health, Innovation and Intellectual Property (IGWG)

http://www.who.int/phi/documents/en/


Public health innovation and ip1

Public Health, Innovation and IP

  • Secretariat for Public Health, Innovation and Intellectual Property (PHI)

    • Established in September 2006

    • Mandate

      • Facilitate implementation of Resolution WHA 59.24

      • Follow-up to the report of the Commission on Intellectual Property Rights, Innovation and Public Health


Resolution wha 59 24 igwg

Resolution WHA 59.24 & IGWG

  • Intergovernmental Working Group (IGWG)

  • Mandate

    • Global Strategy and Plan of Action

      • “Securing an enhanced and sustainable basis for needs-driven, essential health research and development relevant to diseases that disproportionately affect developing countries”

      • Submission to the Sixty-first World Health Assembly in May 2008

    • http://www.who.int/phi/en/

  • What next? May 2008 is approaching rapidly


Intergovernmental working group igwg

Intergovernmental Working Group (IGWG)

  • Final product should go beyond a WHA resolution

  • The “Global Strategy and Plan of Action” will need to be institutionalized / hosted at a suitable home or platform

    • Expertise in neglected diseases R&D

    • Good interface with industry and PDPs

    • Balanced governance involving developed and developing countries

    • Proven record of implementation capacity

    • Long term vision and strategic thinking


6 th round table

6th Round Table


Financing for what kind of innovation

Financing for what kind of innovation?

Hine and Kapeleris (2006) Edward Elgar Publishing Ltd, UK, 259 pp. ISBN-10 1 84376 584 4


The challenge of financing technological innovation vaccines

The challenge of financing technological innovation: Vaccines

  • Historical models of vaccine development

    • Predominantly private sector development

      • Hepatitis B (HBV) vaccine: Merck

    • Public (or nonprofit) sector vaccine design, with handover to the private sector for trials and manufacturing

      • Human papillomavirus (HPV) vaccine

    • Predominantly public-sector development

      • Influenza vaccine: US Army

    • Coordination by a nonprofit entity

      • Salk polio vaccine

IAVI Policy Research Working Paper #14 - R&D Models: Lesson from Vaccine History


The challenge of financing technological innovation vaccines1

The challenge of financing technological innovation: Vaccines

  • Expanded Program for Immunization (EPI) vaccines

    • $0.25 per dose; $1.50 total cost/child

  • New, non-EPI vaccines can cost 10x more

    • $13.50 per fully immunized child

    • The example of Dominican Republic

      • Budget of current national immunization program: $658,190

      • Addition of hepatitis b vaccine: additional $590,040

      • Addition of Hib vaccine: additional $2,880,000

Mahoney et al, Vaccine18:2625-2635, 2000


Commercial trade of pharmaceuticals in brazil

Commercial trade of pharmaceuticals in Brazil

Morel et al (2007) The road to recovery. Nature 449, in press


Oxford conference on innovation and technology transfer for global health

Evolution of Latin America’s economies


Brazil health expenditures per capita us

Brazil: Health expenditures, per capita (US$)


Brazil health expenditures per capita us1

Brazil: Health expenditures, per capita (US$)

2002-05:59.5% up


Public expenditure in health for selected countries us per capita 2003

Public expenditure in health for selected countries (US$ per capita, 2003)


Financing it is not only money that counts

Financing: It is not only money that counts

“Brazil’s approach to the HIV/AIDS epidemic has been characterized by an early public sector response, strong civil society participation, multisectoral mobilization of efforts and resources, a balanced and comprehensive approach to prevention and treatment and the inclusion of a human rights perspective in all strategies”


Financing for what kind of innovation1

Financing for what kind of innovation?

Gardner et al, Health Affairs 2007, 26(4):1052-1061.


Oxford conference on innovation and technology transfer for global health

Science 317:482-487, 27/July/2007


Thank you morel@fiocruz br

Thank youmorel@fiocruz.br

Carlos Morel

Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil


  • Login